These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 34424151)

  • 21. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.
    Roy R; Sk MF; Jonniya NA; Poddar S; Kar P
    J Biomol Struct Dyn; 2022 Sep; 40(14):6556-6568. PubMed ID: 33682642
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    El-Hddad S; Sobhy M; Ayoub A; El-Adl K
    J Biomol Struct Dyn; 2023 Nov; 41(19):9267-9281. PubMed ID: 36399002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an
    Mahanta S; Chowdhury P; Gogoi N; Goswami N; Borah D; Kumar R; Chetia D; Borah P; Buragohain AK; Gogoi B
    J Biomol Struct Dyn; 2021 Jul; 39(10):3802-3811. PubMed ID: 32406317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease.
    C S; S DK; Ragunathan V; Tiwari P; A S; P BD
    J Biomol Struct Dyn; 2022 Feb; 40(2):585-611. PubMed ID: 32897178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Computational identification of potential inhibitory compounds in Indian medicinal and aromatic plant species against major pathogenicity determinants of SARS-CoV-2.
    Sharma S; Sharma A; Bhattacharyya D; Chauhan RS
    J Biomol Struct Dyn; 2022; 40(24):14096-14114. PubMed ID: 34766880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: a computational-aided approach.
    Fadaka AO; Aruleba RT; Sibuyi NRS; Klein A; Madiehe AM; Meyer M
    J Biomol Struct Dyn; 2022 May; 40(8):3416-3427. PubMed ID: 33200673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Finding potent inhibitors for COVID-19 main protease (M
    Motiwale M; Yadav NS; Kumar S; Kushwaha T; Choudhir G; Sharma S; Singour PK
    J Biomol Struct Dyn; 2022 Mar; 40(4):1534-1545. PubMed ID: 33030102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
    Achilonu I; Iwuchukwu EA; Achilonu OJ; Fernandes MA; Sayed Y
    J Mol Graph Model; 2020 Dec; 101():107730. PubMed ID: 32920239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyanobacterial metabolites as promising drug leads against the M
    Naidoo D; Roy A; Kar P; Mutanda T; Anandraj A
    J Biomol Struct Dyn; 2021 Oct; 39(16):6218-6230. PubMed ID: 32691680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
    Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
    J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs.
    Farhat N; Khan AU
    J Mol Model; 2021 Oct; 27(11):312. PubMed ID: 34601658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein-Ligand Docking Simulations with AutoDock4 Focused on the Main Protease of SARS-CoV-2.
    de Azevedo Junior WF; Bitencourt-Ferreira G; Godoy JR; Adriano HMA; Dos Santos Bezerra WA; Dos Santos Soares AM
    Curr Med Chem; 2021; 28(37):7614-7633. PubMed ID: 33781188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity.
    Weng YL; Naik SR; Dingelstad N; Lugo MR; Kalyaanamoorthy S; Ganesan A
    Sci Rep; 2021 Apr; 11(1):7429. PubMed ID: 33795718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA.
    Bello M; Martínez-Muñoz A; Balbuena-Rebolledo I
    J Mol Model; 2020 Nov; 26(12):340. PubMed ID: 33184722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery, synthesis and
    Saravana Mani K; Rajamanikandan S; Prabha B
    J Biomol Struct Dyn; 2023; 41(22):13454-13465. PubMed ID: 36744520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of potential phytochemicals from
    Khan J; Sakib SA; Mahmud S; Khan Z; Islam MN; Sakib MA; Emran TB; Simal-Gandara J
    J Biomol Struct Dyn; 2022; 40(21):10741-10752. PubMed ID: 34278965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
    Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
    Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elucidation of the inhibitory activity of plant-derived SARS-CoV inhibitors and their potential as SARS-CoV-2 inhibitors.
    Bello M; Hasan MK
    J Biomol Struct Dyn; 2022; 40(20):9992-10004. PubMed ID: 34121618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
    Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
    J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M
    Kumar V; Dhanjal JK; Kaul SC; Wadhwa R; Sundar D
    J Biomol Struct Dyn; 2021 Jul; 39(11):3842-3854. PubMed ID: 32431217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.